Last reviewed · How we verify
Iron Sucrose + Erythropoietin
Iron Sucrose + Erythropoietin is a Iron supplement + Erythropoiesis-stimulating agent (ESA) Small molecule drug developed by American Regent, Inc.. It is currently in Phase 3 development for Anemia in patients with chronic kidney disease on dialysis, Iron deficiency anemia in chronic kidney disease patients. Also known as: Venofer.
Iron sucrose replenishes iron stores while erythropoietin stimulates red blood cell production to treat anemia in patients with chronic kidney disease.
Iron sucrose replenishes iron stores while erythropoietin stimulates red blood cell production to treat anemia in patients with chronic kidney disease. Used for Anemia in patients with chronic kidney disease on dialysis, Iron deficiency anemia in chronic kidney disease patients.
At a glance
| Generic name | Iron Sucrose + Erythropoietin |
|---|---|
| Also known as | Venofer |
| Sponsor | American Regent, Inc. |
| Drug class | Iron supplement + Erythropoiesis-stimulating agent (ESA) |
| Target | Iron (ferric hydroxide complex) + Erythropoietin receptor (EPOR) |
| Modality | Small molecule |
| Therapeutic area | Hematology / Nephrology |
| Phase | Phase 3 |
Mechanism of action
Iron sucrose provides bioavailable iron necessary for hemoglobin synthesis, while erythropoietin (EPO) is a recombinant cytokine that stimulates erythropoiesis by binding to EPO receptors on bone marrow progenitor cells. Together, they address both iron deficiency and EPO-responsive anemia, common complications in chronic kidney disease and dialysis patients.
Approved indications
- Anemia in patients with chronic kidney disease on dialysis
- Iron deficiency anemia in chronic kidney disease patients
Common side effects
- Hypertension
- Headache
- Injection site reactions
- Thrombotic events
- Hyperkalemia
Key clinical trials
- Pharmacokinetic of Intravenous Iron Sucrose in Adolescents on Hemodialysis or Peritoneal Dialysis Receiving Epoetin (PHASE2)
- Perioperative Blood Conservation: Role of Combined Iron Supplementation Protocols in Reducing Allogeneic Transfusion (NA)
- Comparison of Oral Iron With IV Iron in Patients With Anemia of Chronic Renal Failure Not on Dialysis (PHASE3)
- The Effect of Combined Iron Protocols on Perioperative Allogeneic Transfusion (NA)
- Effect of the Combined Programme on Perioperative Anaemia（CPPA） (NA)
- Colorado-Oregon Altitude Study (PHASE4)
- Transfusion Savings in Heart Surgery: Impact of Individual Strategy by Erythropoietin and Metabolic Adjustment (ScvO2) (NA)
- Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iron Sucrose + Erythropoietin CI brief — competitive landscape report
- Iron Sucrose + Erythropoietin updates RSS · CI watch RSS
- American Regent, Inc. portfolio CI
Frequently asked questions about Iron Sucrose + Erythropoietin
What is Iron Sucrose + Erythropoietin?
How does Iron Sucrose + Erythropoietin work?
What is Iron Sucrose + Erythropoietin used for?
Who makes Iron Sucrose + Erythropoietin?
Is Iron Sucrose + Erythropoietin also known as anything else?
What drug class is Iron Sucrose + Erythropoietin in?
What development phase is Iron Sucrose + Erythropoietin in?
What are the side effects of Iron Sucrose + Erythropoietin?
What does Iron Sucrose + Erythropoietin target?
Related
- Drug class: All Iron supplement + Erythropoiesis-stimulating agent (ESA) drugs
- Target: All drugs targeting Iron (ferric hydroxide complex) + Erythropoietin receptor (EPOR)
- Manufacturer: American Regent, Inc. — full pipeline
- Therapeutic area: All drugs in Hematology / Nephrology
- Indication: Drugs for Anemia in patients with chronic kidney disease on dialysis
- Indication: Drugs for Iron deficiency anemia in chronic kidney disease patients
- Also known as: Venofer
- Compare: Iron Sucrose + Erythropoietin vs similar drugs
- Pricing: Iron Sucrose + Erythropoietin cost, discount & access